Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
Dimitrios A Karagiannis1, Ioannis D Ladas2, Efstratios Parikakis1, Ilias Georgalas2, Athanasios Kotsolis2, Giorgos Amariotakis1, Vasileios Soumplis1, Panagiotis Mitropoulos11Ophthalmiatrio Eye Hospital of Athens, Athens, Greece; 2First Department of Ophthalmology, Medical School of Athens University...
Main Authors: | Dimitrios A Karagiannis, Ioannis D Ladas, Efstratios Parikakis, et al. |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-11-01
|
Series: | Clinical Interventions in Aging |
Subjects: | |
Online Access: | https://www.dovepress.com/changing-from-bevacizumab-to-ranibizumab-in-age-related-macular-degene-peer-reviewed-article-CIA |
Similar Items
-
Comparison of bevacizumab and ranibizumab in age-related macular degeneration:a systematic review and meta-analysis
by: Xiao-Yu Zhang, et al.
Published: (2014-04-01) -
Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01) -
Bevacizumab vs ranibizumab for neovascular age-related macular degeneration in Chinese patients
by: Zhe-Li Liu, et al.
Published: (2013-04-01) -
Comparison of ranibizumab and bevacizumab in neovascular age-related macular degeneration
by: Huseyin Serdarogullari, et al.
Published: (2014-05-01) -
Bevacizumab for neovascular age-related macular degeneration in Chinese patients in a clinical setting
by: Danny Siu-Chun Ng, et al.
Published: (2016-03-01)